BH4

DRUG4 trials

Sponsors

VA Office of Research and Development, The University of Texas at Arlington, Taipei Veterans General Hospital, Taiwan

Conditions

Cardiovascular DiseasesCardiovascular Risk FactorHeart Failure With Preserved Ejection FractionInflammationPAH DeficiencyPku PhenylketonuriaRheumatologic DiseaseVasoconstriction

Phase 1

Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment

CompletedNCT02530996

VA Office of Research and DevelopmentRheumatologic Disease

Start: 2016-01-01End: 2019-12-31Updated: 2021-04-05

The Effect of Antioxidants on Skin Blood Flow-BH4

CompletedNCT03680573

The University of Texas at ArlingtonCardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction

Start: 2018-01-08End: 2018-05-05Updated: 2018-09-26

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

RecruitingNCT06312748

VA Office of Research and DevelopmentHeart Failure With Preserved Ejection Fraction, Inflammation

Start: 2021-05-19End: 2030-09-30Target: 90Updated: 2025-06-19

Phase 4

BH4 Responsiveness in PAH Deficiency PKU Patients

Taipei Veterans General Hospital, TaiwanPAH Deficiency, Pku Phenylketonuria

Start: 2020-06-30End: 2022-06-30Target: 40Updated: 2020-01-13